Skip to main content
Clinical Trials/NCT04081961
NCT04081961
Completed
Not Applicable

A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing (mHealth) Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms/COPD

Kazakhstan Academy of Preventive Medicine1 site in 1 country27 target enrollmentJune 7, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Signs and Symptoms, Respiratory
Sponsor
Kazakhstan Academy of Preventive Medicine
Enrollment
27
Locations
1
Primary Endpoint
Rate of Recruitment
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This study examines the feasibility and acceptability of using mobile applications and biosensing (mHealth) devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate, blood oxygenation, steps/motion) for a future big-scale study.

Detailed Description

The study is designed to investigate feasibility of using mHealth devices to improve the treatment, assessment, compliance, and outcomes in smokers with and without respiratory symptoms/COPD. The study aims to reveal and address the anticipated barriers to the acceptance and implementation of mHealth devices in this patient population and clinical setting. As is well documented, the more attention patients receive from medical personnel, the better their clinical outcomes. Here we are attempting to use device-driven monitoring applications, interactive reminders, and teaching modules to deliver a constant positive feedback loop to patients to improve their health decisions. Objectives of the study: To assess the feasibility of using mHealth devices in current smokers with and without respiratory symptoms/COPD. To assess the utility (i.e., validity and reproducibility) of mHealth devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate; blood oxygenation; steps/motion; FEV1, FVC, and their ratio; peak expiratory flow \[PEF\]).

Registry
clinicaltrials.gov
Start Date
June 7, 2019
End Date
October 31, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kazakhstan Academy of Preventive Medicine
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Current smokers who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
  • Able to use and willing to be trained to use mHealth devices

Exclusion Criteria

  • COPD exacerbation that has not resolved at least 28 days prior to screening
  • COPD exacerbation occurring after screening but before the first study visit
  • Pneumonia or other respiratory tract infections that have not resolved at least 14 days prior to screening
  • Pneumonia occurring after screening but before the first study visit
  • Active respiratory disorders: tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, bronchial asthma, lung fibrosis, pulmonary hypertension, interstitial lung diseases, or other active pulmonary diseases
  • Any co-morbid medical condition that in the opinion of the investigator would make participation in the study unsafe or unfeasible, including conditions that prohibit completion of exercise testing
  • Use of supplemental oxygen therapy
  • Inability to abstain from smoking during the period in which the participant is admitted to the Kazakhstan Academy of Preventive Medicine (KAPM) COPD Center
  • A history of allergy or hypersensitivity to metal, particularly stainless steel
  • Any vital sign indicator, for example, hypertension or tachycardia at rest that, at the discretion of the investigator, would make participation in the study unsafe or unfeasible

Outcomes

Primary Outcomes

Rate of Recruitment

Time Frame: Baseline

Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.

Rate of Retention

Time Frame: through study completion, an average of 90 days

Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.

Protocol Adherence

Time Frame: through study completion, an average of 90 days

Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.

Study Sites (1)

Loading locations...

Similar Trials